Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies^†

• Pages: 245-250
• First Published: 18 November 2011

A basis for updating our approach to resistant acute leukemia^†

• Pages: 251-257
• First Published: 16 November 2011

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma^†

• Pages: 258-265
• First Published: 08 November 2011

A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression^†

• Pages: 266-271
• First Published: 11 November 2011

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma^†

• Pages: 272-276
• First Published: 17 December 2011

Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin^†

• Pages: 277-283
• First Published: 23 November 2011

A Continuing Medical Education Series

Morphology Update

Solving Clinical Problems in Blood Diseases

Test of the Month

Images in Hematology

Diagnostic Imaging in Hematology

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron^†

• Pages: 308-310
• First Published: 23 November 2011

Leukocyte adhesion deficiency-I variant syndrome (LAD-Iv, LAD-III): Molecular characterization of the defect in an index family^†

• Pages: 311-313
• First Published: 08 November 2011

A case of factor V inhibitor with complete correction of the PT and aPTT upon mixing^†

• Pages: 313-315
• First Published: 07 November 2011

Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects^†

• Pages: 315-317
• First Published: 23 November 2011

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia^†

• Pages: 317-318
• First Published: 23 November 2011

Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146⁺ immunomagnetic enrichment—flow cytometry and soluble E-selectin detection^†

• Pages: 319-320
• First Published: 27 November 2011

Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab^†

• Pages: 321-323
• First Published: 03 December 2011

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia^†

• Pages: 323-326
• First Published: 03 December 2011

Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates^†

• Pages: 326-330
• First Published: 17 December 2011

Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies^†

• Pages: 330-333
• First Published: 17 December 2011

Inpatient management of sickle cell pain: A ‘snapshot’ of current practice^†

• Pages: 333-336
• First Published: 17 December 2011

Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome^†

• Page: 337
• First Published: 08 November 2011

Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome: A response^†

• Pages: 337-338
• First Published: 08 November 2011

More definitions in sickle cell disease: Steady state v base line data^†

• Page: 338
• First Published: 23 November 2011

Drug interaction between lenalidomide and itraconazole^†

• Pages: 338-339
• First Published: 23 November 2011

Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications^{† ‡}

• Pages: 340-346
• First Published: 17 December 2011